A randomized, placebo controlled 4-week study in COPD of QBW251, a potentiator of the cystic fibrosis transmembrane conductance regulator (CFTR) protein

S. Rowe (Birmingham, United States of America), N. Haque (Cambridge, United States of America), S. Gleason (Cambridge, United States of America), I. Jones (Cambridge, United States of America), K. Kulmatycki (Cambridge, United States of America), D. Rowlands (Cambridge, United States of America), S. Grant (Cambridge, United States of America)

Source: International Congress 2018 – Innovative therapies in asthma and COPD
Session: Innovative therapies in asthma and COPD
Session type: Poster Discussion
Number: 617
Disease area: Airway diseases

Congress or journal article abstractSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Rowe (Birmingham, United States of America), N. Haque (Cambridge, United States of America), S. Gleason (Cambridge, United States of America), I. Jones (Cambridge, United States of America), K. Kulmatycki (Cambridge, United States of America), D. Rowlands (Cambridge, United States of America), S. Grant (Cambridge, United States of America). A randomized, placebo controlled 4-week study in COPD of QBW251, a potentiator of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. 617

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: